Here are four notes:
1. Epi proColon is indicated for colorectal cancer screening in average-risk patients who choose not to undergo CRC screening by recommended methods such as colonoscopy and fecal immunochemical tests.
2. The test only requires a blood sample drawn from the patient as part of routine healthcare provider visits.
3. The sample is then analyzed at a local or regional diagnostic laboratory.
4. Epi proColon will be made available in the United States under a joint commercialization agreement with its strategic partner Polymedco.
More articles on GI/endoscopy:
Gastroenterologist to know: Dr. Elaine Barfield of NewYork-Presbyterian Hospital
Cancer recurrence high among patients with HCV-related hepatocellular carcinoma: 3 key insights
Boston Medical Center names Dr. Jason Hall colon & rectal surgery chief: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
